Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its clinical-stage product candidates include immunology, anti-tumor necrosis factor biosimilar candidates, CHS-1420 for adalimumab and CHS-0214 for etanercept, which has completed Phase III clinical programs; ophthalmology biosimilar candidates, CHS-3351 for ranibizumab and CHS-2020 for aflibercept that is in preclinical development; and CHS-131, small molecule therapeutic candidate and other metabolic conditions.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone650-649-3530
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.56 million
Profitability
Miscellaneous
Employees232
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Coherus Biosciences (NASDAQ:CHRS) Frequently Asked Questions
What is Coherus Biosciences' stock symbol?
Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS."
How were Coherus Biosciences' earnings last quarter?
Coherus Biosciences Inc (NASDAQ:CHRS) posted its quarterly earnings data on Thursday, August, 1st. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.40. The biotechnology company had revenue of $83.43 million for the quarter, compared to analysts' expectations of $81.05 million. View Coherus Biosciences' Earnings History.
When is Coherus Biosciences' next earnings date?
What price target have analysts set for CHRS?
7 brokers have issued twelve-month price targets for Coherus Biosciences' stock. Their forecasts range from $25.00 to $45.00. On average, they anticipate Coherus Biosciences' stock price to reach $32.5714 in the next twelve months. This suggests a possible upside of 48.3% from the stock's current price. View Analyst Price Targets for Coherus Biosciences.
What is the consensus analysts' recommendation for Coherus Biosciences?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus Biosciences in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Coherus Biosciences.
What are Wall Street analysts saying about Coherus Biosciences stock?
Here are some recent quotes from research analysts about Coherus Biosciences stock:
- 1. According to Zacks Investment Research, "Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California. " (8/20/2019)
- 2. HC Wainwright analysts commented, "We raise our revenue estimates to $315M (up from $178M) and $387M (from $254M) respectively. Likewise, we now expect Coherus to be profitable over the next two years and raise our EPS estimates to $0.67/share and $0.62/share respectively. We raise our price target to $29 (from $28) since our revised estimates for Udenyca sales increase the value of that franchise in our sum-of-the-parts model. The best biosimilar launch keeps on giving. Coherus’ launch of Udenyca is setting the standard for how quickly it’s gained market traction. It’s even more impressive that Coherus did so as the second product to market, now surpassing Mylan (MYL; not rated) as the share leader in the biosimilar pegfilgrastim market. Coherus now has 13% share of the overall market and the company expects to exit 2019 with 20% share." (8/2/2019)
- 3. Maxim Group analysts commented, "Coherus announced preliminary net sales on UDENYCA of $79M-$84M suggesting swift uptake. This is more than double the 1Q19 figure of $37M. Despite the increase in sales, CHRS shares were down over 13% yesterday." (7/10/2019)
Has Coherus Biosciences been receiving favorable news coverage?
Media stories about CHRS stock have been trending positive recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Coherus Biosciences earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the near term. View News Stories for Coherus Biosciences.
Who are some of Coherus Biosciences' key competitors?
Some companies that are related to Coherus Biosciences include Repligen (RGEN), Moderna (MRNA), argenx (ARGX), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Iovance Biotherapeutics (IOVA), Denali Therapeutics (DNLI), Audentes Therapeutics (BOLD), Sangamo Therapeutics (SGMO) and Regenxbio (RGNX).
What other stocks do shareholders of Coherus Biosciences own?
Who are Coherus Biosciences' key executives?
Coherus Biosciences' management team includes the folowing people:
- Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 64)
- Dr. Jean-Frédéric Viret, Chief Financial Officer (Age 53)
- Dr. Peter K. Watler, Chief Technical Officer (Age 57)
- Dr. V. Bryan Lawlis Jr., Science Director, Director & Member of Supervisory Board (Age 67)
- Mr. Vincent R. Anicetti, Chief Operating Officer (Age 64)
Who are Coherus Biosciences' major shareholders?
Coherus Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.22%), Vanguard Group Inc. (4.24%), Sofinnova Investments Inc. (3.00%), Rock Springs Capital Management LP (2.69%), UBS Asset Management Americas Inc. (2.18%) and Nuveen Asset Management LLC (1.67%). Company insiders that own Coherus Biosciences stock include Barbara K Finck, Dennis M Lanfear, James Healy, Jean-Frederic Viret and Vincent R Anicetti. View Institutional Ownership Trends for Coherus Biosciences.
Which institutional investors are selling Coherus Biosciences stock?
CHRS stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Price T Rowe Associates Inc. MD, Carlson Capital L P, Bank of America Corp DE, Rhenman & Partners Asset Management AB, UBS Asset Management Americas Inc., D. E. Shaw & Co. Inc. and Ardsley Advisory Partners LP. Company insiders that have sold Coherus Biosciences company stock in the last year include Barbara K Finck, Dennis M Lanfear, James Healy, Jean-Frederic Viret and Vincent R Anicetti. View Insider Buying and Selling for Coherus Biosciences.
Which institutional investors are buying Coherus Biosciences stock?
CHRS stock was bought by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Nuveen Asset Management LLC, BlackRock Inc., C WorldWide Group Holding A S, Sio Capital Management LLC, Chartwell Investment Partners LLC, 361 Capital LLC and Parametric Portfolio Associates LLC. View Insider Buying and Selling for Coherus Biosciences.
How do I buy shares of Coherus Biosciences?
Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Coherus Biosciences' stock price today?
One share of CHRS stock can currently be purchased for approximately $21.96.
How big of a company is Coherus Biosciences?
Coherus Biosciences has a market capitalization of $1.53 billion and generates $1.56 million in revenue each year. The biotechnology company earns $-209,340,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Coherus Biosciences employs 232 workers across the globe.View Additional Information About Coherus Biosciences.
What is Coherus Biosciences' official website?
How can I contact Coherus Biosciences?
Coherus Biosciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]
MarketBeat Community Rating for Coherus Biosciences (NASDAQ CHRS)
MarketBeat's community ratings are surveys of what our community members think about Coherus Biosciences and other stocks. Vote "Outperform" if you believe CHRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
